Verastem Business Summary

Verastem, Inc. (VSTM) is a commercial-stage biopharmaceutical firm that generates revenue primarily through the sale of its AVMAPKI FAKZYNJA CO-PACK, the first FDA-approved treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). The company operates through two primary pillars: its commercial oncology segment, which achieved approximately $30.9 million in net product revenue during its 2025 launch year, and its clinical development pipeline focused on small molecule inhibitors of the RAS/MAPK pathway, notably the KRAS G12D inhibitor VS-7375. Verastem competes with biotechnology peers such as MannKind Corporation, Celldex Therapeutics, and BioCryst Pharmaceuticals. It occupies a specialized market niche by leveraging dual RAF/MEK and FAK inhibition to address resistant solid tumors, with management projecting its commercial operations to become self-sustaining by the second half of 2026. Verastem was co-founded by Michelle Detwiler and Dr. Robert Weinberg, a pioneer in cancer genetics who continues to serve as Chair of the Scientific Advisory Board. The executive leadership is led by President and CEO Dan Paterson, who brings over three decades of oncology drug development experience, and President of Development Michael Kauffman, M.D., Ph.D., a former Karyopharm CEO who transitioned from the board to the executive team in December 2025. The leadership suite is further supported by Chief Scientific Officer Jonathan Pachter and CFO Daniel Calkins, while the board is chaired by John Johnson, a veteran of Eli Lilly and Johnson & Johnson. The company is backed by a high concentration of institutional investors, including Balyasny Asset Management, AIGH Capital Management, and Goldman Sachs, which collectively support Verastem’s strategic focus on RAS/MAPK pathway-driven malignancies.